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Abstract
Background: There is no evidence to date on whether transcriptional regulators are able to shift the balance between
mitochondrial fusion and fission events through selective control of gene expression.
Methodology/Principal Findings: Here, we demonstrate that reduced mitochondrial size observed in knock-out mice for
the transcriptional regulator PGC-1b is associated with a selective reduction in Mitofusin 2 (Mfn2) expression, a
mitochondrial fusion protein. This decrease in Mfn2 is specific since expression of the remaining components of
mitochondrial fusion and fission machinery were not affected. Furthermore, PGC-1b increases mitochondrial fusion and
elongates mitochondrial tubules. This PGC-1b-induced elongation specifically requires Mfn2 as this process is absent in
Mfn2-ablated cells. Finally, we show that PGC-1b increases Mfn2 promoter activity and transcription by coactivating the
nuclear receptor Estrogen Related Receptor a (ERRa).
Conclusions/Significance: Taken together, our data reveal a novel mechanism by which mammalian cells control
mitochondrial fusion. In addition, we describe a novel role of PGC-1b in mitochondrial physiology, namely the control of
mitochondrial fusion mainly through Mfn2.
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Introduction
Mitochondria are dynamic organelles whose morphology is
regulated by fusion and fission processes. A growing body of
evidence shows the relevance of these shaping processes in the
control of mitochondrial activity and cell metabolism [1–7]. Several
genes encoding mitochondrial fusion and fission proteins have been
recently identified. Mammalian proteins involved in mitochondrial
fission are Fission 1 homologue protein (Fis1) and Dynamin-related
protein 1 (Drp1). Similarly, Mitofusin 1 (Mfn1), Mitofusin 2 (Mfn2)
and Optic Atrophy gene 1 (OPA1) are proteins that participate in
mitochondrial fusion in mammals [8]. However, there are no
evidences to date that demonstrate the ability of an upstream or
transcriptional regulator to shift the balance between mitochondrial
fusion and fission events by selective regulation of these proteins.
Several reports provide evidence that Mfn2 protein elicits
pleiotropic effects which may be involved in pathology. For
instance, Mfn2 is mutated in Charcot Marie Tooth type 2A
neuropathy [9] and, interestingly, some of these mutants cause
selective defects in mitochondrial fusion [10], reduction in
mitochondrial axonal transport [11] or defects in mitochondrial
coupling leading to inefficient mitochondria [12]. Defective Mfn2
may also contribute to impaired mitochondrial function in the
context of obesity and type 2 diabetes. This notion is supported by
the observation that muscle Mfn2 expression is reduced in these
patients [1,13]. In addition, we have previously reported that
Mfn2 can modulate mitochondrial activity through changes in the
electron transport chain (ETC) and this modulation is independent
of its role in mitochondrial morphology [1,6].
Peroxisome proliferator-activated receptor c coactivator-1
(PGC-1) a and b are important positive regulators of mitochon-
drial activity and biogenesis in mouse skeletal muscle [14–17].
Despite these similarities, PGC-1a and PGC-1b display low
overall sequence identity, with the highest percentatges found in
two particular domains (activation and RNA recognition domains,
with identities of 40% and 50% respectively) [15]. Furthermore,
key mitochondrial processes, such as organelle biogenesis and
uncoupling, are differentially regulated by these homologues. For
instance, in C2C12 muscle cells, PGC-1a but not PGC-1b,
increases mitochondrial uncoupling, whereas PGC-1b causes a
larger increase in mitochondrial volume than PGC-1a under the
same conditions [18]. In addition, while PGC-1b expression in
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distinct tissues is unaffected by physiological processes character-
ized by increased energy expenditure, such as cold exposure (in
brown adipose tissue), fasting (in liver) or exercise (in muscle),
PGC-1a is highly regulated at the transcriptional level under
similar physiological challenges [15–17]. These data suggest that
PGC-1b likely controls basal mitochondrial biogenesis, whereas
PGC-1a controls stimulated or regulated mitochondrial activity.
In keeping with this view, PGC-1b expression is higher than PGC-
1a expression in primary muscle cells under basal conditions [19].
The functional independency in mitochondrial physiology of
these homologues is further illustrated by the phenotypes of PGC-
1a and PGC-1b knockout (KO) mice. In both animal models, a
general defect in the electron transport chain (ETC) system has
been described, thereby demonstrating that PGC-1a does not fully
compensate the effects of PGC-1b on mitochondria or vice versa
[20–23]. Furthermore, several mitochondrial phenotypes de-
scribed in the particular case of PGC-1b-ablated mice cannot be
completely explained by impairment of the ETC system. For
instance, muscle and liver from PGC-1b KO mouse show a
reduction of mitochondrial volume without changes in mitochon-
dria number [20,23]. This decreased mitochondrial volume
together with impaired ETC gene expression may explain the
mitochondrial respiration defect found only in muscle strips and
not in isolated mitochondria [20]. In keeping with these data, this
reduction in mitochondrial size is absent in PGC-1a KO mouse
under basal conditions, probably due to normal PGC-1b
expression [21,24]. Of note, despite all these differences, both
genes show a diminished expression in the context of type 2
diabetes, suggesting an impairment of mitochondrial effects
selectively regulated by each homologue in this disease [25,26].
We previously reported that PGC-1a was able to induce Mfn2
transcription and that mitochondrial activity regulated by PGC-1a
partly depends on correct Mfn2 expression. However, effects on
mitochondrial fusion were not determined [27]. In the light of
these results and the PGC-1b control of basal mitochondrial
biogenesis, we aimed to determine whether PGC-1b was able to
control Mfn2 transcription and, therefore, if the mitochondrial
dynamics balance could be modulated by transcriptional regula-
tion. Here, we address these questions by determining the role of
PGC-1b in the control of mitochondrial fusion using a multi-
approach strategy that combines Mfn2 KO cells, PGC-1b-
overexpressing muscle cells and PGC-1b-ablated mice.
Results
PGC-1b induces Mfn2 transcription through ERRa
coactivation
Our initial aim was to determine whether PGC-1b regulates the
expression of Mfn2 in C2C12 muscle cells. Differentiated C2C12
cells show low levels of PGC-1b mRNA as assessed by Northern
blot [18] and by real-time PCR (data not shown). To this end,
C2C12 myotubes were transduced either with a mouse PGC-1b
adenovirus or with a control LacZ adenovirus. Mfn2 mRNA levels
doubled in PGC-1b-expressing muscle cells compared to control
transduced myotubes (Fig. 1A). To demonstrate that PGC-1b
directly increases Mfn2 transcription, we transfected 10T1/2
mouse fibroblasts or HeLa cells with a construct containing a 2-kb
fragment (21982/+45) of the Mfn2 promoter fused to a luciferase
reporter gene, together with an irrelevant vector (Basal) or mouse
PGC-1b expression vector (PGC-1b). PGC-1b markedly en-
hanced Mfn2 promoter activity (10.360.9- and 4.260.6-fold
values over basal Mfn2 promoter activity in 10T1/2 and HeLa
respectively, Fig. 1B). In a previous study, using electrophoretic
mobility shift and chromatin immunoprecipitation assays, we
showed that ERRa binds to Mfn2 promoter between nucleotides
2459/2396 [27]. This DNA region contains three putative boxes
with the capacity to bind nuclear receptors, where box 2 is critical
for Mfn2 promoter response to PGC-1a coactivation of ERRa
[27]. On the basis of these observations, we determined whether
PGC-1b coactivated ERRa through box 2 in a similar way as
PGC-1a. We transfected 10T1/2 cells with a construct containing
a 2459/2352 Mfn2 promoter fragment fused to a luciferase
reporter gene or with a mutated version of the same fragment that
disrupted box 2 [27]. We observed a marked coactivation of
ERRa by PGC-1b in the 2459/2352 Mfn2 promoter fragment
(Fig. 1C). This effect was completely blunted when box 2 was
disrupted (11.961.09 vs. 2.860.6-fold over basal promoter
activity, p = 0.001, Fig. 1C). Furthermore, cancellation of box 2
markedly reduced the activation driven by PGC-1b (7.060.5 vs.
1.960.5, p = 0.001) or by ERRa (2.260.1 vs. 1.660.2, p = 0.04),
although residual activation was still present. Similar results were
obtained when the 2- kb Mfn2 promoter was cotransfected with
ERRa or PGC-1b (Figure S1).
PGC-1b causes a large induction of Mfn2 protein levels
To determine whether PGC-1b-mediated Mfn2 transcription
leads to enhanced Mfn2 protein expression, we transduced C2C12
myotubes with PGC-1b or two distinct control adenoviruses at a
multiplicity of infection (MOI) of 1, 10 or 100. Total protein
extracts and mitochondrial-enriched fractions were obtained and
analyzed by Western blot. PGC-1b induced Mfn2 in muscle cells
(Fig. 2A) and a direct relationship between PGC-1b adenoviral
dose and Mfn2 protein induction was detected (Fig. 2A). PGC-1b
also increased the cellular content of the constitutive mitochon-
drial protein Porin (Fig. 2A), used as a measure of mitochondrial
mass. Densitometric quantification of Porin induction at MOI 100
showed a 1.860.2-fold increase in total lysates (p = 0.01, Figure
S2) and 1.4560.003-fold in mitochondrial-enriched fractions
(p = 0.002, Fig. 2C). Porin induction values in total lysates are
consistent with the increase in mitochondrial mass volume
reported in PGC-1b-overexpressing C2C12 muscle cells [18].
On the basis of the effects of PGC-1b on Mfn2 and Porin
expression, we also analyzed whether this coactivator regulates the
expression of other proteins involved in mitochondrial dynamics
and in the ETC system. PGC-1b-transduced myotubes induced
the expression of Mfn1, OPA1, Drp1 and Fis1 (Fig. 2B) in
mitochondrial-enriched extracts (1.7-, 2.2-, 1.4-, or 2.1-fold values
over basal values, respectively) to a level similar to that detected for
Porin (1.45-fold stimulation, Fig. 2C). Mfn2 displayed a signifi-
cantly higher increase in expression compared to Porin abundance
in mitochondrial-enriched extracts (4.3-fold induction, Fig. 2C).
When data were expressed as protein levels relative to Porin
expression, we only detected significant stimulation of Mfn2 and
Fis1 in response to PGC-1b over-expression (Figure S3). Similar
results were obtained in total lysates (data not shown). This
superior induction of Mfn2 protein was also detected in C2C12
myoblasts (Fig. 3A).
We also analyzed several subunits of the ETC system in
mitochondrial-enriched fractions from C2C12 myotubes trans-
duced at MOI 100 (Fig. 2B,C). All the subunits of complexes I, II,
III, IV and V studied were induced in response to PGC-1b
(Fig. 2B,C), and the extent of induction was similar to that detected
in Porin levels (ranging from 1.3- to 2.1-fold increase).
PGC-1b changes mitochondrial morphology and
increases the rate of mitochondrial fusion
As PGC-1b induces Mfn2 expression, we next determined
whether it was linked to changes in mitochondrial morphology. To
PGC-1b Controls Mfn2
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this end, we immunofluorescently labelled mitochondria from
C2C12 myoblasts transduced with PGC-1b or LacZ adenovirus.
PGC-1b caused an increase in the length of mitochondrial tubules
(Fig. 3B) in most myoblasts (59% vs. 33%, in PGC-1b and in
control cells, respectively, p = 0.003) (Fig. 3C). This increased
mitochondrial size induced by PGC-1b overexpression was also
observed by transmission electron microscopy, showing normal
cristae morphology (Fig. 3D). To demonstrate that this increase in
mitochondrial length was linked to an increase in mitochondrial
fusion, we performed a polyethylene glycol-(PEG) mediated cell
fusion assay by using two distinct C2C12 lines stably expressing
mitochondrial matrix-targeted GFP (mtGFP) or red fluorescent
protein (mtRFP) [28]. Four hours after PEG and in the presence of
cycloheximide, a significantly higher percentage (73% vs. 55% in
PGC-1b and control cells, respectively, p = 0.01) (Fig. 3E) of
polykaryons from C2C12 transduced with PGC-1b showed a
higher level of mitochondrial matrix content mixing than control
LacZ polykaryons (that is mtGFP and mtRFP exchange due to
mitochondrial fusion and displayed as yellow mitochondria)
(Fig. 3F). This higher mtGFP and mtRFP mixing indicated an
increase in the rate of mitochondrial fusion induced by
overexpression of PGC-1b. In agreement with previous data
[18], the overexpression of PGC-1b in C2C12 myoblasts under
these conditions also increased a ,50% the mitochondrial
membrane potential values measured using the fluorescent probe
JC-1 (data not shown).
Mfn2 is required for PGC-1b-induced changes in
mitochondrial morphology
To study whether the change in mitochondrial morphology
induced by PGC-1b was mediated mainly through Mfn2 activity, we
used mouse embryonic fibroblasts (MEFs) from wild-type and from
Mfn2 or Mfn1 KO mice [29]. Overexpression of PGC-1b led to an
increase in mitochondrial length of wild-type (Fig. 4A,B) and Mfn1
KO MEFs (data not shown), similarly as observed in C2C12
myoblasts (Fig. 3B,C). Importantly, PGC-1b gain-of- function was
unable to promote mitochondrial elongation in Mfn2 KO MEFs
(Fig. 4C,D), in conditions in which ETC subunits Cox4 and Uqcrc2
Figure 1. PGC-1b increases Mfn2 transcription through nuclear receptor ERRa. (A) Total RNA was obtained from C2C12 myotubes
transduced with LacZ (white bars) or PGC-1b (black bars) adenovirus at a MOI 100 from 3 independent experiments in duplicate. Mfn2 and b-Actin
mRNA levels were measured by real-time PCR. Results are mean6SEM and are expressed relative to b-Actin values, *, statistical difference at p,0.001.
(B) Transcriptional activity of 21982/+45 human Mfn2 promoter was determined by luciferase activity (corrected by renilla activity) in 10T1/2 and
HeLa cells. Results are mean6SEM from 3 independent experiments performed in triplicate. Cells were transfected with 200 ng of an irrelevant vector
(Basal, white bars) or PGC-1b expression vector (PGC-1b, black bars) and expressed relative to the basal group; * statistical difference at p,0.05. (C)
Luciferase activity (corrected by renilla) from 10T1/2 cells transfected with a 2459/2352 Mfn2 promoter fragment containing a mutation that
disrupted box 2 (2459/2352 Box 2 Mut, black bars) or with the wild-type fragment (2459/2352, white bars), together with an irrelevant vector
(Basal), ERRa, 200 ng of PGC-1b or ERRa+PGC-1b expression plasmids. Mean6SEM values from 3 independent transfection experiments performed in
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were increased 1.6- and 1.5-fold respectively (data not shown). These
data demonstrate the requirement of Mfn2 expression for PGC-1b-
mediated changes in mitochondrial morphology.
PGC-1b KO mice show Mfn2 repression in skeletal muscle
and miocardium
We next studied the effects of in vivo ablation of PGC-1b on
Mfn2 expression in gastrocnemius muscles. Mfn2 protein levels
were reduced by approximately 50% in KO mice (Fig. 5A).
Reduction of Mfn2 levels was relatively specific as indicated by the
absence of major changes in proteins involved in mitochondrial
dynamics, i.e., Mfn1, OPA1, Drp1 and Fis1 (Fig. 5B). Similar
results were obtained using mitochondrial fractions (data not
shown). Reduced Mfn2 protein expression paralleled lower levels
of Mfn2 mRNA (Fig. 5C).
Soleus muscle from PGC-1b KO mice also shows a decrease in
complex IV (subunits Cox4 and Cox5b) mRNA levels [20]. This
observation led us to study whether the protein levels of Cox4 and
other subunits of complexes I, II, III and V were also altered in
gastrocnemius muscle of this mouse model. These mice displayed
approximately a ,40% reduction in complex V (ATP5a1) and III
(Uqcrc2) (Fig. 5D). Complex IV (Cox4) showed a,25% reduction
and complex I (Ndufa9) a ,20% decrease while no changes were
observed in complex II protein levels (Sdha) (Fig. 5D).
The heart is one of the organs with the highest expression of
PGC-1b [16]. Interestingly, heart lysates from KO mice displayed
a clear reduction in Mfn2 protein levels (WT 1.0060.06, KO
0.5760.09, p = 0.0015; data not shown), suggesting the impair-
ment of this regulatory pathway also in cardiac muscle.
Hepatic Mfn2 levels are reduced in PGC-1b KO mice
Liver is a crucial metabolic organ and shows high mitochondrial
activity. PGC-1b KO mice also show reduced hepatic ETC gene
expression [20]. On the basis of these observations, we next
examined whether hepatic Mfn2 expression was altered in PGC-
1b KO mice. Hepatic lysates from PGC-1b KO mice were
obtained and analyzed by Western blot. Mfn2 protein levels were
reduced by 65% in KO livers compared to the control group
(Fig. 6A). This decrease was specific since among other proteins
involved in mitochondrial dynamics only a modest 12% increase
in Fis1 levels was detected (Fig. 6B). Similar results were obtained
in mitochondrial fractions (data not shown). Mfn2 mRNA levels
Figure 2. Effect of PGC-1b on the expression of Mfn2, other proteins involved in mitochondrial dynamics, Porin and ETC subunits.
Total lysates and mitochondrial fractions were obtained from C2C12 myotubes 48 h after adenoviral transduction, and the expression of proteins was
analyzed by Western blot (40 mg). Representative films of a single experiment from four independent differentiation and transduction experiments
are shown. (A) Total lysates and mitochondrial fractions of non-transduced myotubes (NT), transduced with LacZ or GFP control adenovirus at a MOI
100 (control adenovirus at a MOI 1 and 10 displayed no changes, data not shown) or with PGC-1b adenovirus at a MOI 1, 10 or 100 were probed with
anti-Mfn2 and Porin antibodies. (B) Specific antibodies were used to detect mitochondrial dynamics proteins (Mfn1,OPA1, Drp1 and Fis1) and single
subunits from each complex of the ETC (complex I, Ndufa9; complex II, Sdha; complex III, Uqcrc2; complex IV, Cox4 and complex V, ATP5a1) in
mitochondrial fractions of non-transduced (NT) or transduced C2C12 myotubes at a MOI 100 with LacZ or PGC-1b adenovirus. (C) Quantification
analysis of protein levels of mitochondrial dynamics components and the ETC subunits from complexes I to V detected by Western blot. Mean6SEM
of Non- (white bars) , LacZ- (grey bars) or PGC-1b- (black bars) transduced C2C12 myotubes from n=4 independent differentiation and transduction
(MOI 100) experiments. *, statistical difference compared to LacZ transduction, p,0.05.#, statistical difference compared to Porin induction, p,0.05.
doi:10.1371/journal.pone.0003613.g002
PGC-1b Controls Mfn2
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were also reduced by 25% in livers from PGC-1b KO mice
(Fig. 6C).
Hepatic PGC-1b expression is markedly induced in mice fed a
high fat diet, which is, to our knowledge, the only situation
reported to induce PGC-1b mRNA levels in adult tissues.
Therefore, we analyzed hepatic Mfn2 expression in wild-type
and PGC-1b KO mice fed a high fat diet during 6 months. We
observed a higher reduction in Mfn2 mRNA levels in livers from
PGC-1b KO mice fed a high fat diet (by 45%, data not shown)
compared to PGC-1b KO mice fed a chow diet (by 25 %). This
was specific to Mfn2 and no changes in Mfn1 expression were
detected under normal or high fat diet conditions (data not shown).
Figure 3. PGC-1b increases the rate of mitochondrial fusion and changes mitochondrial morphology. (A) Representative Western blot of
three independent experiments of C2C12 myoblasts transduced with LacZ or PGC-1b adenovirus at a MOI 200 during 48 h. 40 mg of protein from
lysates were loaded and Mfn2, Mfn1, Opa1, Drp1, Fis1 and Porin were detected with specific antibodies. (B) Representative images from a duplicate of
one of the same three independent transduction experiments performed in panel (A). Mitochondria were labelled with anti-Cox1 antibody detected
with a secondary antibody conjugated to Alexa 594. Scale bar, 10 mm. (C) C2C12 myoblasts quantification and classification attending to
mitochondrial tubule length (150–200 cells counted per transduction). Myoblasts with a mean mitochondrial tubule length ,4 mm were considered
‘‘Short’’ and .4 mm were considered ‘‘Long’’. Results are mean6SEM and expressed as percentage of total C2C12 myoblasts counted from three
independent transduction experiments with LacZ (white bars) or PGC-1b (black bars) at MOI of 200. *, statistical difference at p,0.01. (D) Electron
microscopy images of C2C12 myoblasts transduced with LacZ or PGC-1b adenovirus as in panel (A) were taken at 40.000x magnification . Scale bar
500 nm. (E) 4 hours after PEG, polykaryons of C2C12 myoblasts transduced as in (A) were counted attending to mtGFP (mitochondrial matrix-
targeted green fluorescent protein) and mtRFP (mitochondrial matrix-targeted red fluorescent protein) mixing (detected as yellow mitochondria).
Polykaryons classified as ‘‘Low’’ displayed ,50% of mixed mtGFP and mtRFP (yellow mitochondria). Polykaryons classified as ‘‘High’’ displayed $50%
of yellow mitochondria. Graphs show mean6SEM of percentage of total polykaryons counted from three independent cell fusion experiments and
transduction experiments with LacZ (white bars) or PGC-1b (black bars) at MOI of 200. *, statistical difference at p = 0.02. (F) Representative images
from one of three independent transduction and polyethylene glycol-mediated (PEG) cell fusion experiments. C2C12 myoblasts stably expressing
mitochondrial matrix-targeted green fluorescent protein (mtGFP) or red fluorescent protein (mtRFP) were transduced with LacZ or PGC-1b
adenovirus as in panel (A). Polykaryons were fixed 4 h after 30’’–40’’ PEG treatment. During these 4 h, cells were incubated in growth medium with
100 mg/ml of cycloheximide to inhibit de novo synthesis of mtGFP and mtRFP. Degree of fusion is directly proportional to mixing of mtGFP and
mtRFP (yellow mitochondria). Scale bar, 10 mm.
doi:10.1371/journal.pone.0003613.g003
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The expression of some ETC subunits was examined in liver
mitochondrial fractions of PGC-1b KO mice (Fig. 6D). Cox4
levels were reduced by 65%. Subunits of complexes I and V
displayed moderate reductions (,20% and ,30%, respectively),
while those of complexes II and III remained unaltered (Fig. 6D).
Discussion
In the present study we demonstrate that mitochondrial dynamics
balance can be shifted towards fusion by transcriptional regulation.
More specifically, we show that PGC-1b is a regulator of
mitochondrial fusion through its effects of selectively promoting
Mfn2 expression upon coactivation of ERRa. This new role of PGC-
1b in mitochondrial physiology has been demonstrated using both in
vitro (muscle cells) and in vivo (PGC-1b-ablated mice) approaches.
Firstly, we have shown that PGC-1b overexpression in muscle cells
regulates mitochondrial dynamics through a mechanism that
involves the preferential induction of Mfn2 expression, among other
mitochondrial dynamics effectors such as Mfn1, OPA1, Drp1 and
Fis1. Furthermore, PGC-1b gain-of-function results in an elongation
of mitochondrial tubules, which is linked to an increased
mitochondrial fusion. Importantly, the effects of PGC-1b promoting
mitochondrial elongation are not observed in Mfn2-ablated cells,
thereby demonstrating that Mfn2 activity is essential for PGC-1b-
mediated changes in mitochondrial dynamics.
The relevance of these observations is confirmed by our in vivo
data showing that PGC-1b KO mice have a specific reduction of
Mfn2 expression in skeletal muscle whereas Mfn1, OPA1, Drp1
and Fis1 levels are maintained. In fact, this preferential regulation
of Mfn2 protein levels could explain the reduction in mitochon-
drial volume, without changes in mitochondria number, observed
in liver and muscle from PGC-1b loss-of-function mice [20,23].
We propose that Mfn2-impaired function in PGC-1b KO mice
prevents a normal rate of mitochondrial fusion while physiological
Figure 4. Mfn2 is required for PGC-1b changes in mitochondrial morphology. (A) Representative immunocytochemistry images (performed
as in Fig. 3B) from one of three independent cotransfection experiments with an empty vector (Control) or PGC-1b- encoding vector (PGC-1b) and
GFP (ratio GFP:PGC-1b 1:10) of wild-type mouse embryonic fibroblasts (MEFs). Transfected cells were visualized by GFP fluorescence (data not
shown). Scale bar, 10 mm. (B) Wild type mouse embryonic fibroblasts (MEF) quantification and classification attending to mitochondrial tubule length
(50-75 transfected cells counted per independent experiment). Wild type MEFs with a mean mitochondrial tubule length ,4 mm were considered
‘‘Short’’ and.4 mmwere considered ‘‘Long’’. ‘‘Perinuclear’’ MEFs displayed most mitochondria surrounding the nucleus (see Figure S4) and almost no
‘‘Fragmented’’ cells (with tiny spherical mitochondria, see Figure S4) were observed in transfected wild type MEFs. Results are mean6SEM and
expressed as percentage of total transfected wild type MEFs counted from three independent cotransfection experiments with an empty vector
(white bars) or PGC-1b (black bars) with GFP (empty vector/PGC-1b : GFP ratio 10:1). Transfected cells were observed by GFP fluorescence (data not
shown). *, statistical difference at p,0.02. (C) Representative immunocytochemistry images (performed as in Fig. 3B) from one of three independent
cotransfection experiments with an empty vector (Control) or PGC-1b- encoding vector (PGC-1b) and GFP (ratio GFP:PGC-1b 1:10) of Mfn2 2/2mouse
embryonic fibroblasts (MEFs). Transfected cells were visualized by GFP fluorescence (data not shown). Scale bar, 10 mm. (D) Mfn22/2mouse embryonic
fibroblasts (MEF) quantification and classification attending to mitochondrial tubule length (100–250 transfected cells counted per independent
experiment). Mfn2 2/2 MEFs with a mean mitochondrial tubule length ,4 mm were considered ‘‘Short’’ and .4 mm were considered ‘‘Long’’.
‘‘Perinuclear’’ MEFs displayed most mitochondria surrounding the nucleus (see Figure S4) and a significant percentage of ‘‘Fragmented’’ cells (with tiny
spherical mitochondria, see Figure S4) were observed in transfected Mfn2 2/2 MEFs. Results are mean6SEM and expressed as percentage of total
transfected Mfn22/2 MEFs counted from three independent cotransfection experiments with an empty vector (white bars) or PGC-1b (black bars) with
GFP (empty vector/PGC-1b : GFP ratio 10:1). Transfected cells were observed by GFP fluorescence (data not shown).
doi:10.1371/journal.pone.0003613.g004
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mitochondrial fission events remain unaffected, thereby resulting
in smaller mitochondria as previously reported for Mfn2 KO or
antisense cells [1,30].
Several lines of evidence demonstrate the relevance of
maintaining a proper balance between fusion and fission processes
for the specific mitochondrial activity required by distinct cell types
[1–6]. In this regard, PGC-1b expression is higher in tissues with
marked mitochondrial activity (such as liver, muscle and heart), a
similar pattern to that reported for Mfn2 [1,16]. In addition, we
have found that PGC-1b regulates Mfn2 expression in liver,
skeletal muscle and heart, as PGC-1b KO mice show a marked
decrease in Mfn2 in those tissues. The correlational data
mentioned before together with the observations obtained in
skeletal muscle, heart and liver from PGC-1b KO mice indicate
that PGC-1b controls basal expression of Mfn2 in these tissues.
On the basis of these observations, we propose that increased
mitochondrial fusion caused by PGC-1b-induced Mfn2 contributes
to a fully optimal mitochondrial activity in muscle and liver tissues,
which may be defective in skeletal muscle of type 2 diabetic patients.
Furthermore, we propose that PGC-1b controls basal mitochondrial
fusion in skeletal muscle, whereas PGC-1a would probably control
mitochondrial fusion in high energy expenditure situations, such as
cold-exposure or exercise, conditions which largely induce Mfn2
expression [27]. This is supported by the fact that PGC-1b
expression is higher than PGC-1a expression in skeletal muscle
under basal conditions and by the lack of a decrease in mitochondrial
size in PGC-1a KO mice [19,24]. In keeping with this proposal, our
data permit to explain the observation of a defective mitochondrial
respiration found in muscle strips but not in isolated mitochondria
from PGC-1b KO mice under basal conditions [20]. In isolated
mitochondria, the integrity of the mitochondrial network and
dynamics inside the cell is not maintained and therefore defects in
mitochondrial activity secondary to abnormal mitochondrial
dynamics are not detectable.
Here, we have also examined the mechanism by which PGC-1b
induces Mfn2 transcription, and have identified ERRa as the key
transcription factor coactivated by PGC-1b on the Mfn2 promoter.
The effect of ERRa and PGC-1b occurred at the level of box 2
(located in the 2459/2352 promoter region), although PGC-1b
also displayed additional stimulatory actions on the Mfn2 promoter.
The same box 2 region is the major component required for PGC-
1a activation of the Mfn2 promoter [27]. On the basis of these data,
we conclude that PGC-1a and PGC-1b display a common
mechanism of activation of the Mfn2 promoter, through nuclear
receptor ERRa. However, despite using the same response elements,
decreased expression of Mfn2 induced by genetic ablation of PGC-
Figure 5. PGC-1b KO mice show a specific decrease in Mfn2 expression in skeletal muscle. Gastrocnemius muscles from 4- or 8-month-old
wild-type (WT, black bars) or PGC-1b KO male mice (KO, white bars) were used to obtain total RNA and protein. (A) Representative image from a
Western blot with specific detection of Mfn2 and Porin in muscle lysates. Graph represents mean6SEM of Mfn2 levels relative to Porin values (n = 6
mice per group). *, statistical difference at p,0.01. (B) Abundance of proteins involved in mitochondrial dynamics (Mfn1, OPA1, Drp1 and Fis1) in
total lysates. Graph represents mean6SEM of protein levels relative to Porin values (n = 6 mice per group). (C) Real-time PCR analysis of Mfn2 from WT
and KO mice. Graph represents mean6SEM and data are expressed as values of Mfn2 relative to 36B4 mRNA levels (n = 8 mice per group). *, statistical
difference at p,0.01. (D) Abundance of the ETC subunits in mitochondrial fractions (n = 6 mice per group). Subunits of complexes I to V of the ETC
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1b in mice cannot be counteracted by PGC-1a action, as shown in
liver, heart and skeletal muscle of PGC-1b KO mice, in which Mfn2
expression is decreased, probably due to the low expression of PGC-
1a under basal conditions.
In summary, we provide evidence that mitochondrial dynamics
balance is selectively controlled by a transcriptional regulator,
unravelling an upstream mediator of mitochondrial fusion.
Furthermore, we also provide evidence of a novel role of PGC-
1b in mitochondrial physiology. Given the crosstalk between
mitochondrial activity and dynamics, together with reduced Mfn2
and PGC-1b expression in type 2 diabetes, we conclude that the
pathway reported here is not only relevant for the thorough
explanation of mitochondrial dynamics regulation and the overall
mitochondrial effects of PGC-1b, but also may provide the basis
for the correct understanding of the alterations of mitochondrial
metabolism associated with type 2 diabetes.
Materials and Methods
Animal Care and tissue collection
All animal protocols were approved as previously published
[20]. Mice were cared for according to the Guiding Principles for
Research Involving Animals and Human Beings. Tissue collection
was performed as previously published [20].
Cell culture, transfections, luciferase assays and
adenoviral transductions
10 T1/2 , HeLa , HEK293A and C2C12 cell lines were grown
as reported [27].
10 T1/2 fibroblasts and HeLa cells were transfected in 24-well
plates at 40% confluence using Lipofectamine 2000 (Invitrogen)
and harvested 36 h after. Transfected DNA plasmids were
1.04 mg/well and ratios/well were 75 ng to 200 ng of PGC-1b,
200 ng of ERRa, 600 ng of reporter, 40 ng of Renilla and up to
1.04 mg/well of pcDNA 3.1 as an irrelevant vector. 10 ml of total
lysates from 10 T1/2 or HeLa cells were analysed using Dual-
GloTM Luciferase Assay System from Promega following the
manufacturer’s instructions.
Mouse embryonic fibroblasts (MEFs) from wild-type, Mfn1 KO
and Mfn2 KO mice [29] were seeded in coverslips 24 h before
cotransfection with an empty vector or with a plasmid encoding
mouse PGC-1b and GFP (empty vector/PGC-1b:GFP ratio 10:1) in
6-well plates at 40% confluence using Transfectin reagent (1 mg DNA
: 3 ml reagent) (BioRad). Transfection efficiencies for wild-type MEFs
were,5–15% and for Mfn22/2MEFs were,40–60% (observed
by GFP fluorescence). MEFs were fixed 48 h after transfection.
C2C12 differentiated myotubes were obtained 3 days after
adding differentiation medium to 90% confluent cells (5% Horse
Serum from Gibco, P/S and 25 mM HEPES). Myotubes were
Figure 6. Hepatic Mfn2 levels are diminished in PGC-1b KO mice. Livers from 4- or 8- month-old wild-type (WT, black bars) and PGC-1b KO male
mice (KO, white bars) were used to obtain total RNA and protein. (A) Representative image from a Western blot with specific detection of Mfn2 and Porin
in liver lysates fromWT or KOmice. Graph represents mean6SEM of Mfn2 levels related to Porin (n=6 mice per group). *, statistical difference at p,0.01.
(B) Abundance of proteins involved inmitochondrial dynamics in total lysates (Mfn1, OPA1, Drp1 and Fis1). Graph represents mean6SEM of protein levels
relative to Porin values (n=6 mice per group). (C) Real-time PCR analysis of Mfn2 from WT and KO mice. Graph represents mean6SEM and data are
expressed as values of Mfn2 relative to 36B4 mRNA levels (n=8 mice per group). *, statistical difference at p,0.01. (D) Abundance of the ETC subunits in
mitochondrial fractions (n=6 mice per group). Single subunits of complexes I to V of the ETC were detected with specific antibodies. Graph represents
mean6SEM and data are expressed as values relative to Porin expression. *, statistical difference at p,0.05.
doi:10.1371/journal.pone.0003613.g006
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transduced with a LacZ- or a mouse PGC-1b-encoding adenovirus
at a multiplicity of infection (MOI) of 1, 10 or 100 during 24 h and
processed 2 days after transduction. Myoblasts were transduced at
a MOI 200, as they are less sensitive to adenoviral transduction
compared to myotubes [31]. Myotubes transduced at a MOI 100
and myoblasts at a MOI 200 displayed 99% of transduced cells
(data not shown).
Plasmids and adenoviruses
Constructs and adenovirus were previously described [27,32].
Adenovirus titer was determined in HEK293A cells as previously
described [6].
Real Time PCR analysis
Taqman Probes 20X (Applied Biosystems) for Mfn2, PGC-1b
and 3B64 were used. b-Actin primers, RNA isolation, cDNA
synthesis and PCR conditions were as described in [27,32] .
Relative expression levels were calculated by DCt and the standard
curve method [27,32].
Protein extracts and subcellular fractionation
Total lysates and mitochondria from C2C12 myoblasts and
myotubes, and skeletal muscle, liver and heart from PGC-1b KO
mice were isolated by differential centrifugation as previously
described [6]. Protein obtained was quantified by the BCA
method (Pierce).
Western blot and antibodies used
SDS-PAGE, loading controls and densitometric analysis were
performed as previously described [6]. Images were processed with
Adobe Photoshop CS adjusting levels to reduce background.
The monoclonal antibodies against the ETC system subunits
and Porin were described in our previous study [6]. OPA1 and
Drp1 antibodies were purchased from BD Biosciences Pharmin-
gen (San Diego, California, USA) and used at a 1/1000 dilution.
Polyclonal antibodies generated in rabbit: serum raised against
Mfn2 [6] was affinity purified by Sulfo-Link Kit (Pierce, Rockford,
Illinois, USA), conjugating the immunogenic peptide (Eurogentec,
Liege, Belgium) with an N-terminal cysteine (Nter C-
LGPKNSRRALMGYNDQVQRP Cter) to a column and used
at dilution 1/500. Mfn1 antibody was from Legros et al. [28] and
Fis1 antibody from BioVision (Mountain View, California, USA)
(1/500). All antibodies were diluted in PBS 5% dry non-fat milk
and incubated overnight at 4uC with orbital agitation. Detection of
primary antibodies was performed as previously described [6].
Transmission electron microscopy
Cells were fixed with PFA 2%/Glutatraldehyde 0.125% in the
plate and scrapped gently after 60’ of fixation at room
temperature. The rest of the protocol was performed as previously
reported [6]. Images were taken at 40000x magnification in the
electron microscopy platform, Serveis Cientı´fico-Te`cnics (SCT),
Universtitat de Barcelona.
Immunocytochemistry and microscopy
Immunocytochemistry of C2C12 myoblasts and MEFs was
performed as previously described, using the fluorochrome Texas
red (conjugated to an anti-mouse secondary antibody from
Molecular probes) [6] and coverslips were mounted in Mowiol
(Calbiochem). Images were taken at room temperature with a
Leica laser scanning confocal microscope SP2 (laser excitation
594 nm) using a 63X oil immersion objective (1.4). Images were
magnified 5 times with Leica Lite H software.
Images without magnification (with 30–40 cells per field) were
used to count 150–200 cells, which were classified in two groups.
Cells with a mean mitochondrial length .4 mm were considered
to have elongated mitochondria (Long), the rest were considered
short (Short). Mean mitochondrial length was determined (in
images magnified 5 times) by measuring the length of 40–60
mitochondrial filaments per cell with Leica Lite H software.
In the particular case of MEFs, transfected cells were counted
(GFP-positive, laser 488 nm excitation, from 60 to 200 cells
counted per independent experiment and transfection). In Mfn1
and Mfn2 2/2, we observed two additional cell populations, on
the basis of their mitochondrial morphology (see Figure S4), which
we named ‘‘fragmented’’, given that most mitochondria from these
cells were spherical (similar percentages as previously reported,
[3]) , and ‘‘perinuclear’’, for which almost all mitochondria located
surrounding the nucleus.
C2C12 myoblasts stably expressing mtGFP and mtRFP
Mitochondrial matrix-targeted GFP and RFP [28] were PCR
amplified (with 59 BamHI and 39 EcoRI primers) and cloned into
pGEM-T easy vector (Promega). Inserts, cloned into pGEM-T,
were obtained by EcoRI-BamHI (New England Biolabs) digestion
and were ligated (New England Biolabs) into BamHI EcoRI sites
of pWPXL lentiviral vector (gift from D. Bach and D. Trono from
EPH, Lausanne). Lentiviruses were produced and titrated as
described [33]. C2C12 myoblasts were also transduced as
described [33].
Polyethylene glycol-mediated (PEG) cell fusion assay
This assay was adapted from Legros et al. [28]. PEG was
purchased from BDH and DMEM from Gibco. Twenty-four
hours after transduction of C2C12 cells stably expressing mtGFP
and mtRFP, cells were washed with sterile PBS, trypsinized and
counted; 1.8.105 C2C12 mtGFP and 1.8.105 C2C12 mtDsRed
were coseeded on 25-mm coverslips in 6-well plates. Forty-eight
hours after transduction, cells were washed three times with
DMEM and then incubated during 30’’–40’’ with 500 ml of
PEG:DMEM (1:1 weight:volume). Cells were then washed gently
three times with growth medium plus cycloheximide (100 mg/ml)
and incubated with this medium. Four hours after of 30’’–40’’
incubation with PEG, cells were fixed (PFA 4% in PBS) and
mounted at room temperature.
Polykaryons from cell fusion experiments were counted (75–100
polykaryons per independent experiment) using a Nikon E1000
fluorescence microscope (FITC filter 465–490 nm excitation for
mtGFP and G2A filter 510–560 nm for mtRFP) and were classified
on the basis of their level of colocalization. Polykaryons classified as
‘‘High’’ contained at least 50% of their green and red mitochondrial
matrix-targeted proteins mixed due to mitochondrial fusion (yellow
mitochondria). Polykaryons with lower percentages were considered
‘‘Low’’. Single stack representative images shown were taken with
Leica laser scanning confocal microscope SP2 (laser emission
488 nm for mtGFP and 561 nm for mtRFP) using a 63X oil
immersion objective (1.4) at room temperature. Images were
magnified 2–3 times with Leica Lite H software.
Statistical analysis
Two-tailed t student test was performed in all experiments. *, #
show statistical significance at distinct p values under 0.05.
Supplemental Material
Figure S1 shows gene reporter experiments performed with a
2 Kb fragment of Mfn2 promoter and its mutated version without
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a functional Box 2. Figure S2 shows the quantification analysis of
Porin induction by PGC-1b in total lysates of C2C12 differenti-
ated muscle cells. Figure S3 shows the effect of PGC-1b
overexpression on the abundance of different mitochondrial
proteins expressed relative to Porin. Figure S4 shows representa-
tive images from different mitochondrial morphologies observed in
Mfn2 mouse embryonic fibroblasts.
Supporting Information
Figure S1 Box 2 mutation in Mfn2 promoter blocks PGC-1b-
dependent ERRa coactivation. 10T1/2 cells were transfected with
a 2-Kb (21982/+45) fragment of Mfn2 promoter (white bars) or
its mutated version (Mfn2 promoter Box2 Mut, black bars)
together with an irrelevant vector (Basal), 75 ng of PGC-1b
expression vector, ERRa or with PGC-1b+ERRa. Graphs display
mean6SEM luciferase related to renilla activity values of 3
independent transfection experiments performed in triplicate.
*Statistical difference compared to basal group, p,0.05.
#Statistical difference compared to wild-type Mfn2 promoter,
p,0.05.
Found at: doi:10.1371/journal.pone.0003613.s001 (0.52 MB TIF)
Figure S2 Porin expression is increased ,78% in C2C12
myotubes transduced with PGC-1b adenovirus. Total lysates were
obtained from non-transduced (NT), LacZ- or PGC-1b-trans-
duced C2C12 myotubes at MOI 100 during 48 h and analyzed by
Western blot with specific antibodies raised against Porin. Graphs
show mean6SEM of Porin densitometric quantification levels
related to LacZ Porin values from 4 independent differentiation
and transduction experiments. *Statistical difference, p = 0.01.
Found at: doi:10.1371/journal.pone.0003613.s002 (0.43 MB TIF)
Figure S3 Normalization of mitochondrial dynamics compo-
nents and ETC subunits protein levels induced by PGC-1b by
Porin levels. Quantification analysis of protein levels of mitochon-
drial dynamics components and the ETC subunits from complexes
I to V detected by Western blot and related to porin levels.
Mean6SEM of Non- (white bars) , LacZ- (grey bars) or PGC-1b-
(black bars) transduced C2C12 myotubes from n = 4 independent
differentiation and transduction (MOI 100) experiments. *,
statistical difference compared to LacZ transduction, p,0.05.
Found at: doi:10.1371/journal.pone.0003613.s003 (0.74 MB TIF)
Figure S4 Representative images from distinct transfected Mfn2
2/2 MEFs classified on the basis of mitochondrial morphology.
Mitochondria were labelled with anti-Cox1 antibody detected
with a secondary antibody conjugated to Alexa 594. Scale bar,
10 mm.
Found at: doi:10.1371/journal.pone.0003613.s004 (5.83 MB TIF)
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